Adult
Aged
Aged, 80 and over
Chemoradiotherapy
/ mortality
Female
Fluorodeoxyglucose F18
Follow-Up Studies
Humans
Lung Neoplasms
/ diagnostic imaging
Male
Middle Aged
Positron Emission Tomography Computed Tomography
/ methods
Prognosis
Radiopharmaceuticals
Small Cell Lung Carcinoma
/ diagnostic imaging
Survival Rate
(18)F-FDG PET/CT
lung cancer
small-cell
staging
survival
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
28
01
2019
revised:
14
03
2019
accepted:
17
03
2019
pubmed:
20
4
2019
medline:
26
6
2020
entrez:
20
4
2019
Statut:
ppublish
Résumé
We used phase-3 CONVERT trial data to investigate the impact of fludeoxyglucose F 18 ( CONVERT randomized patients with limited-stage SCLC to twice-daily (45 Gy in 30 fractions) or once-daily (66 Gy in 33 fractions) chemoradiotherapy. Patients were divided into two groups in this unplanned analysis: those staged with conventional imaging (contrast-enhanced thorax and abdomen CT and brain imaging with or without bone scintigraphy) and those staged with Data on a total of 540 patients were analyzed. Compared with patients who underwent conventional imaging (n = 231), patients also staged with In CONVERT, survival outcomes were not significantly different in patients staged with or without
Identifiants
pubmed: 31002954
pii: S1556-0864(19)30282-5
doi: 10.1016/j.jtho.2019.03.023
pmc: PMC6616906
pii:
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1296-1305Subventions
Organisme : Cancer Research UK
ID : 8154
Pays : United Kingdom
Informations de copyright
Copyright © 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.
Références
J Thorac Oncol. 2009 Sep;4(9):1049-59
pubmed: 19652623
Nucl Med Mol Imaging. 2018 Feb;52(1):31-38
pubmed: 29391910
J Natl Cancer Inst. 2007 Dec 5;99(23):1753-67
pubmed: 18042932
Acta Radiol. 2018 Sep;59(9):1082-1090
pubmed: 29256260
Acad Radiol. 2016 Aug;23(8):1047-56
pubmed: 27259379
J Thorac Oncol. 2017 Oct;12(10):1561-1570
pubmed: 28648948
Eur Radiol. 2016 Sep;26(9):3155-61
pubmed: 26685851
BMJ Open. 2016 Jan 20;6(1):e009849
pubmed: 26792218
J Thorac Oncol. 2016 Apr;11(4):453-74
pubmed: 26829312
Am J Med. 1969 Apr;46(4):516-25
pubmed: 5791000
J Clin Oncol. 2004 Aug 15;22(16):3248-54
pubmed: 15310768
JAMA Oncol. 2019 Mar 1;5(3):e185335
pubmed: 30520977
N Engl J Med. 1999 Aug 12;341(7):476-84
pubmed: 10441603
Thorax. 2010 Oct;65 Suppl 3:iii1-27
pubmed: 20940263
N Engl J Med. 2007 Aug 16;357(7):664-72
pubmed: 17699816
Lancet Oncol. 2017 Aug;18(8):1116-1125
pubmed: 28642008
J Thorac Oncol. 2012 Jun;7(6):1015-20
pubmed: 22534816
Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):329-36
pubmed: 19782478
N Engl J Med. 1999 Jan 28;340(4):265-71
pubmed: 9920950
Lancet. 2015 Jan 3;385(9962):36-42
pubmed: 25230595
J Clin Oncol. 2007 Sep 10;25(26):4137-45
pubmed: 17827464
J Clin Oncol. 2015 Dec 1;33(34):4106-11
pubmed: 26351333
Lancet Oncol. 2017 May;18(5):663-671
pubmed: 28343976
Lung Cancer. 2011 Aug;73(2):121-6
pubmed: 21524814
J Clin Oncol. 2006 Oct 1;24(28):4539-44
pubmed: 17008692
Ann Oncol. 2013 Oct;24 Suppl 6:vi99-105
pubmed: 23813929
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Clin Lung Cancer. 2016 May;17(3):184-8
pubmed: 26320828
N Engl J Med. 2018 Dec 6;379(23):2220-2229
pubmed: 30280641
Clin Oncol (R Coll Radiol). 2016 Nov;28(11):712-719
pubmed: 27522475